

Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis

Julie Morisset, MD; Kerri A. Johannson, MD; Eric Vittinghoff, PhD; Carlos Aravena, MD; Brett M. Elicker, MD; Kirk D. Jones, MD; Charlene D. Fell, MD; Helene Manganas, MD; Bruno-Pierre Dubé, MD; Paul J. Wolters, MD; Harold R. Collard, MD, FCCP; Christopher J. Ryerson, MD; and Brett Ley, MD

CHEST 2017; 151(3):619-625

Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.

© 2016 AMERICAN COLLEGE OF CHEST PHYSICIANS. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: 10.1016/j.chest.2016.10.029

e-Table 1. Comparison of baseline characteristics between the UCSF patients included in the study and those excluded due to lack of follow-up

Characteristics	Included patients (n = 38)	Excluded patients n=30)	p-value
Mean age (SD), years	60.7 (12.3)	67.5 (8.86)	0.009
Male - n (%)	23 (60.5)	13 (43.3)	0.158
Ever smoker - n (%)	16 (42.1)	18 (60.0)	0.143
Surgical lung biopsy - n/total (%)	31 (81.6)	15 (50.0)	0.006
Identified exposure - n/total (%)	17 (44.7)	15 (50.0)	0.666
PFTs at MMF or AZA initiation			
Mean FVC % predicted (SD)	66.8 (16.9)	68.2 (15.2)	0.724
Mean DLCO% predicted (SD)	49.2 (15.5)	48.3 (13.6)	0.803

Abbreviations: PFTs = pulmonary function tests; MMF = mycophenolate mofetil; ZA = azathioprine; FVC = forced vital capacity; DLCO = diffusing capacity for carbon monoxide.